Medtronic (NYSE:MDT) is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions). The company also supplies a range of hospital products and services that support perioperative and procedural care.
Medtronic operates on a global scale, serving customers in more than 150 countries through a combination of direct sales, distribution partners and clinical service programs. Its customers include hospitals, ambulatory surgery centers and specialty clinics, and the company emphasizes clinical collaboration, training and post-market support as part of its commercial approach. Medtronic maintains a significant research-and-development focus to advance new therapies and meet evolving regulatory and clinical requirements.
The company’s executive leadership team is responsible for steering Medtronic’s strategy around innovation, reimbursement and market access; Geoffrey S. Martha has served as chief executive in recent years. Medtronic’s business model centers on developing technology-enabled therapies, expanding clinical evidence, and scaling commercial capabilities to address chronic and acute conditions across diverse geographies.
